Compare / Foundayo vs Wegovy pill: cost
Foundayo vs Wegovy pill: cost
The two weight-management pills, each with its own price ladder.
- Foundayo Tablet: $149 to $299 across 6 strengths, per month, higher if a refill is more than 45 days late.[1]
- Wegovy Tablet: $149 to $299 across 4 strengths, per month.[2]
- Medicare GLP-1 Bridge ($50 a month for people who qualify): covers Foundayo Tablet, Wegovy Tablet.[3][4]
Strengths of different drugs are not equivalent doses. The tables below sit side by side; they are not meant to be read row by row across drugs.
Foundayo Tablet
| Strength | Price per month | Conditions in the official listing | List price (WAC) |
|---|---|---|---|
| 0.8 mg | $149 | — | $649 |
| 2.5 mg | $149 | Temporary price through Dec 31, 2026. Regular price $199. | $649 |
| 5.5 mg | $199 | Temporary price through Dec 31, 2026. Regular price $299. | $649 |
| 9 mg | $299 | — | $649 |
| 14.5 mg | $299 | On-time refills. If a refill is more than 45 days after the last one: $349. | $649 |
| 17.2 mg | $299 | On-time refills. If a refill is more than 45 days after the last one: $349. | $649 |
LillyDirect (Eli Lilly self-pay). TrumpRx lists the price for 30 tablets. The FDA label dosing is one tablet once daily.
Wegovy Tablet
| Strength | Price per month | Conditions in the official listing | List price (WAC) |
|---|---|---|---|
| 1.5 mg | $149 | — | $1,349.02 |
| 4 mg | $199 | — | $1,349.02 |
| 9 mg | $299 | — | $1,349.02 |
| 25 mg | $299 | — | $1,349.02 |
NovoCare Pharmacy (Novo Nordisk self-pay). Offer terms on TrumpRx: one month is one bottle of 30 tablets.
From the FDA labels
Foundayo
FDA-approved uses · label 1
FOUNDAYOTM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use
Concomitant use with another GLP-1 receptor agonist is not recommended.
Dosage forms and strengths · label 3
FOUNDAYO tablets are available as orforglipron:
- 0.8 mg: pink round tablet debossed with “L” on one side and “G1” on the other side
- 2.5 mg: light yellow round tablet debossed with “L” on one side and “G2” on the other side
- 5.5 mg: grayish purple round tablet debossed with “L” on one side and “G3” on the other side
- 9 mg: pink modified oval tablet debossed with “Lilly” on one side and “G4” on the other side
- 14.5 mg: light yellow modified oval tablet debossed with “Lilly” on one side and “G5” on the other side
- 17.2 mg: grayish purple modified oval tablet debossed with “Lilly” on one side and “G6” on the other side
Wegovy pill
FDA-approved uses · label 1
WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:
- • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
- • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. o adults with overweight in the presence of at least one weight-related comorbid condition.
- o adults and pediatric patients aged 12 years and older with obesity.
- o adults with overweight in the presence of at least one weight-related comorbid condition.
- • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:
- • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
- • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use
Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Dosage forms and strengths · label 3
Injection: clear, colorless solution available as follows:
Single-Dose Pens | |
Dose per Injection | Total Strength per Total Volume |
0.25 mg | 0.25 mg/0.5 mL |
0.5 mg | 0.5 mg/0.5 mL |
1 mg | 1 mg/0.5 mL |
1.7 mg | 1.7 mg/0.75 mL |
2.4 mg | 2.4 mg/0.75 mL |
7.2 mg (WEGOVY HD) | 7.2 mg/0.75 mL |
Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch) | |
Dose per Injection | Total Strength per Total Volume |
2.4 mg | 9.6 mg/3 mL (3.2 mg/mL) |
Single-Dose Syringes | |
Dose per Injection | Total Strength per Total Volume |
0.25 mg | 0.25 mg/0.5 mL |
0.5 mg | 0.5 mg/0.5 mL |
1 mg | 1 mg/0.5 mL |
1.7 mg | 1.7 mg/0.75 mL |
2.4 mg | 2.4 mg/0.75 mL |
Tablets: available as:
Tablet Strength | Description |
1.5 mg | White to light yellow, round shaped debossed with “1.5” on one side and “novo” on the other side |
4 mg | White to light yellow, round shaped debossed with “4” on one side and “novo” on the other side |
9 mg | White to light yellow, round shaped debossed with “9” on one side and “novo” on the other side |
25 mg | White to light yellow, oval shaped debossed with “25” on one side and “novo” on the other side |
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Official sources for this page
“The price for the 2.5mg dose is temporarily reduced through December 31, 2026. Regular price is $199. The price for the 5.5mg dose is temporarily reduced through December 31, 2026. Regular price is $299. *Eligibility required, terms and conditions apply. Review full terms and conditions.”
TrumpRx.gov: Foundayo Tablet listing · as of Oct 17, 2026“Self-pay pricing varies by dose. Eligibility and restrictions apply. Government beneficiaries excluded. One month is defined as one bottle containing 30 tablets. Novo Nordisk reserves the right to modify or cancel this offer at any time. See full Terms and Conditions.”
TrumpRx.gov: Wegovy Tablet listing · as of Oct 17, 2026“Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo® (tablet) Wegovy® (injection or tablet) Zepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens).”
Medicare.gov: Weight loss drugs · as of Oct 17, 2026“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
Medicare.gov: Weight loss drugs · as of Oct 17, 2026